Prognostic implications in myelodysplastic syndromes: A review of 62 cases

Leukemia & Lymphoma
T HiguchiK Fujita

Abstract

We retrospectively reviewed 62 MDS patients (15 RA, 3 RARS, 10 CMML, 20 RAEB, 14 RAEBT) to clarify the current problems in their management. Median survival of RA and RARS patients was 67.9 months and significantly longer than that of CMML, RAEB, or RAEB-T patients with median survivals of 16.1, 16.8, and 9.5 months, respectively. Karyotypic abnormalities were observed in 58% of the patients examined. Forty-two patients died, 16 (38%) of leukemic transformation and 21(50%) of bone marrow failure. While most of the RAEB-T patients of all ages and all the RAEB patients diagnosed below 60 years of age died of transformation, 70% of the older RAEB patients died of infection. Prognosis after transformation was poor and 12 patients died within two months. These results indicate that management after transformation and treatment against infection in RAEB patients with advanced age are crucial to improve the prognosis in MDS.

References

Aug 1, 1992·British Journal of Haematology·A D WhiteA Jacobs
Mar 1, 1991·The American Journal of Medicine·C PomeroyG A Filice
Oct 1, 1990·British Journal of Haematology·A A GeddesA Jacobs
Aug 1, 1988·European Journal of Haematology·M van der WeideM M Langenhuijsen
Mar 1, 1988·American Journal of Hematology·S GarcíaG F Sanz
Mar 1, 1985·British Journal of Haematology·G J MuftiD Machin
Oct 1, 1983·British Journal of Haematology·M A BoogaertsW Goossens
Oct 1, 1983·Journal of Clinical Pathology·S MartinJ A Child

❮ Previous
Next ❯

Related Concepts

Related Feeds

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.